Interferon in relapsing-remitting multiple sclerosis
| Autor: | George PA Rice, Barbara Incorvaia, Luca M. Munari, George Ebers, Chris Polman, Roberto D'Amico, Elena Parmelli, Graziella Filippini |
|---|---|
| Rok vydání: | 2001 |
| Předmět: |
medicine.medical_specialty
Intention-to-treat analysis medicine.diagnostic_test business.industry Multiple sclerosis MEDLINE Magnetic resonance imaging Disease medicine.disease Placebo Recombinant Proteins Multiple Sclerosis Relapsing-Remitting Meta-analysis Internal medicine Interferon Type I Humans Medicine Pharmacology (medical) business Adverse effect Randomized Controlled Trials as Topic |
| Zdroj: | The Cochrane Library |
| ISSN: | 1465-1858 |
| DOI: | 10.1002/14651858.cd002002 |
| Popis: | BACKGROUND Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS). OBJECTIVES We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS. SEARCH STRATEGY Of 208 articles identified by a predefined search strategy, seven of these, reporting randomised trials, met all the selection criteria and form the subject of this review. SELECTION CRITERIA The trials selected were double-blind, placebo-controlled, randomised trials of RRMS patients who were treated with recombinant interferon, given by the subcutaneous or the intramuscular route. DATA COLLECTION AND ANALYSIS The quality of the trials was variable, with substantial methodological inadequacies in allocation concealment, high proportion and incomplete description of dropouts and failure to adhere to the principles of intention to treat analysis. The baseline characteristics were largely comparable between treatment and placebo groups. Because of prominent treatment-associated side effects, which could be easily identified by patients, these trials could be considered as single blind rather than double-blind. MAIN RESULTS Although 1215 patients were included in this review, only 919 (76%) contributed to the results concerning exacerbations and progression of the disease at two years. Specifically interferon significantly reduced the occurrence of exacerbations (RR =0.80, 95% CI [0.73,0.88], p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|